GlassScriptPhysician profile
Amy Butler
NPI 1124670658
$2,217.78
in general payments reported to CMS, 2019-2025
29 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $1,105 · 2023: $474 · 2024: $123 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $641.42 | 2022-2023 | Axonics |
| Astellas Pharma US INC | $271.54 | 2022-2024 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $165.28 | 2022-2023 | Erleada |
| Pfizer INC. | $154.25 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $147.72 | 2021-2025 | Breztri |
| Genzyme Corporation | $133.30 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $115.68 | 2023 | Orgovyx, Gemtesa |
| Genentech USA, INC. | $65.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.70 | 2021 | |
| Abbvie INC. | $57.68 | 2023-2025 | |
| Kaleo, INC. | $39.93 | 2021-2022 | |
| Amgen INC. | $36.23 | 2021-2022 | |
| Boston Scientific Corporation | $35.06 | 2022-2024 | |
| 180 Medical, INC. | $30.00 | 2024 | Self-Cath |
| Phadia US INC. | $22.46 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $20.87 | 2023 | Stravix |
| Urogen Pharma, INC. | $20.51 | 2023 | Jelmyto |
| Regeneron Healthcare Solutions, INC. | $20.49 | 2022 | |
| Myovant Sciences INC. | $19.83 | 2022 | |
| Endo Pharmaceuticals INC. | $18.56 | 2023 | Aveed, Xiaflex, Edex |
| Tris Pharma INC | $17.63 | 2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $16.67 | 2023 | |
| Glaxosmithkline, LLC. | $16.26 | 2025 | Pediarix, Bexsero, Penmenvy |
| Abbott Laboratories | $16.14 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.50 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.44 | 2021 | |
| Lilly USA, LLC | $14.15 | 2025 | Zepbound, Mounjaro |
| Progenics Pharmaceuticals, INC. | $13.66 | 2024 | |
| Optinose US, INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.